CTSO

#4457
Cytosorbents Corp.
0.59 USD
0.00%
Sector: Atención Sanitaria
Básica: USD
Divisa de beneficio: USD
Rango diario
0.58
0.61
Rango anual
0.50
1.39
Cambio diario
0.00%
Variación mensual
-18.06%
Variación en los últimos 6 meses
-35.87%
Cambio anual
-43.27%
Cierres anteriores
0.59
Abrir
0.61
Bid
Ask
Mínimo
0.58
High
0.61
Volumen
3
Ver el calendario completo

Financials

Visión general Informes Estadísticas
Trimestre Año
  • Market Capitalization 36.99 M
  • Employee 129
  • Founded 1997
  • CEO N/A
  • Website www.cytosorbents.com
  • Headquarter Delaware, United States
  • FIGI BBG000C3P8V0
  • Industry Technology
Ingresos totales
Beneficio neto
Beneficio básico por acción
Deuda total
Flujo de caja libre
Efectivo y equivalentes
Ratio precio/beneficio
-4.92
Relación precio/flujo de caja
1.07

Cytosorbents Corporation

CytoSorbents Corporation is a publicly traded company located in Princeton, New Jersey. CytoSorbents sells a cytokine adsorbing column — a blood purification technology based on porous polymer beads that act like sponges in an attempt to remove harmful inflammatory mediators like Cytokines, Bilirubin, Myoglobin from the blood. The use of hemoperfusion columns is generally limited to patients who are critically ill in high-resource counties, and they require a patient to be connected to a hemofiltration system such as Dialysis, Hemofiltration Cardiopulmonary bypass or ECMO. Other blood purification devices are using different technologies with different performance parameters. This is including polymyxin B hemoperfusion columns, which failed to show significance in a clinical trial for sepsis. The CytoSorb technology has actually the largest body of clinical data confirming safety and efficacy. Clinicaltrials.gov is giving an overview over running research projects. CytoSorbents was awarded a $3.8 million contract by Defense Advanced Research Projects Agency for its “Dialysis-Like Therapeutics” program to treat sepsis by removing cytokines and pathogen-derived toxins.

Noticias